NCT03799744 - Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions

Head and Neck NeoplasmsCarcinoma, Squamous Cell of Head and NeckMetastasisRecurrence

Interventions

GENETIC

VCN-01

Dose level 1: 3.3x10\^12 viral particles/patient and Dose level 2: 1x10\^13 viral particles/patient

BIOLOGICAL

Durvalumab

Dose: 1500 mg Q4W

Trial Locations (2)

Institut Català D'Oncologia, L'Hospitalet de Llobregat

Hospital Universitari Vall D'Hebron, Barcelona